Citations

Showing 10 of 108119 citations.

Molecular characterization of Novel ATM fusions in chronic lymphocytic leukemia and T-cell prolymphocytic leukemia
Kanagal‐Shamanna, Rashmi , Bao, Haiyan, Kearney, Hutton M. , Smoley, Stephanie A., Luthra, Rajyalakshmi , Yang, Hui , Zhang, Shanshan , Lu, Xinyan , Kearney, Hutton, Smoley, Stephanie , Kanagal-Shamanna, Rashmi , Tang, Zhenya , Lin, Pei , Wu, Depei , Medeiros, L. Jeffrey

Mayo Clinic

Leukemia & Lymphoma | December 13, 2021 | Volume: 63 | Issue: 4 | Pages: 865-875

10.1080/10428194.2021.2010061 | PMID 34898335 Get It

Toward Individualized Prediction of Response to Methotrexate in Early Rheumatoid Arthritis: A Pharmacogenomics‐Driven Machine Learning Approach
Myasoedova, Elena , Athreya, Arjun P. , Crowson, Cynthia S. , Davis, John M. , Walchak, Robert C., Bongartz, Tim, Tak, Paul P. , Vollenhoven, Ronald van , Padyukov, Leonid , Emery, Paul , Morgan, Ann W , Wang, Liewei , Weinshilboum, Richard M. , Matteson, Eric L. , Carlson, Erin, Tak, Paul P , Padyukov, Leonid , Emery, Paul , Morgan, Ann , Matteson, Eric L , Myasoedova, Elena , Davis, John M , Warrington, Kenneth J. , Carlson, Erin E. , Kalari, Krishna R. , Weinshilboum, Richard M.

Mayo Clinic

Arthritis Care & Research | December 13, 2021 | Volume: 74 | Issue: 6 | Pages: 879-888

10.1002/acr.24834 | PMID 34902228 Get It

Objective To test the ability of machine learning (ML) approaches with clinical and genomic biomarkers to predict methotrexate treatment response in patients with early rheumatoid arthritis (RA). Methods Demographic, clinical, and genomic data from 643 patients of European ancestry with early RA (mean age 54 years; 70% female) subdivided into a training (n = 336) and validation cohort (n = 307) were used. The genomic data comprised 160 single‐nucleotide polymorphisms (SNPs) previously associated with RA or methotrexate metabolism. Response to methotrexate monotherapy was defined as good or moderate by the European Alliance of Associations for Rheumatology (EULAR) response criteria at the 3‐month follow‐up. Supervised ML methods were trained with 5 repeats and 10‐fold cross‐validation using the training cohort. Prediction performance was validated in the independent validation cohort. Results Supervised ML methods combining age, sex, smoking, rheumatoid factor, baseline Disease Activity Score in 28 joints (DAS28) scores and 160 SNPs predicted EULAR response at 3 months with the area under the receiver operating curve of 0.84 ( P = 0.05) in the training cohort and achieved a prediction accuracy of 76% ( P = 0.05) in the validation cohort (sensitivity 72%, specificity 77%). Intergenic SNPs rs12446816, rs13385025, rs113798271, and ATIC (rs2372536) had variable importance above 60.0 and along with baseline DAS28 scores were among the top predictors of methotrexate response. Conclusion Pharmacogenomic biomarkers combined with baseline DAS28 scores can be useful in predicting response to methotrexate in patients with early RA. Applying ML to predict treatment response holds promise for guiding effective RA treatment choices, including timely escalation of RA therapies.
NCCN Guidelines® Insights: Squamous Cell Skin Cancer, Version 1.2022
Schmults, Chrysalyne D. , Blitzblau, Rachel , Aasi, Sumaira Z. , Alam, Murad , Andersen, James, Bordeaux, Jeremy S. , Chen, Pei-Ling , Chin, Robert , Contreras, Carlo M. , DiMaio, Dominick J. , Farma, Jeffrey M. , Ghosh, Karthik, Grekin, Roy C. , Harms, Kelly L. , Holder, Ashley M. , Lukens, John N. , Medina, Theresa , Nehal, Kishwer S. , Nghiem, Paul , Patel, Tejesh , Scott, Jeffrey, Sekulić, Aleksandar , Shaha, Ashok R. , Stebbins, William G., Thomas, Valencia D., Xu, Yaohui , McCullough, Beth, Dwyer, Mary A., Nguyen, Mai Q., Alam, Murad , Baumann, Brian C. , Donigan, Jessica M. , Ho, Alan L. , Medina, Theresa Michelle , Park, Soohyung , Puzanov, Igor , Srivastava, Divya

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 13, 2021 | Volume: 19 | Issue: 12 | Pages: 1382-1394

10.6004/jnccn.2021.0059 | PMID 34902824 Get It

The NCCN Guidelines for Squamous Cell Skin Cancer provide recommendations for diagnostic workup, clinical stage, and treatment options for patients with cutaneous squamous cell carcinoma. The NCCN panel meets annually to discuss updates to the guidelines based on comments from panel members and the Institutional Review, as well as submissions from within NCCN and external organizations. These NCCN Guidelines Insights focus on the introduction of a new surgical recommendation terminology (peripheral and deep en face margin assessment), as well as recent updates on topical prophylaxis, immunotherapy for regional and metastatic disease, and radiation therapy.
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Ganti, Apar Kishor , Bassetti, M. , Blakely, Collin M. , Chiang, Anne C. , D’Amico, Thomas A., D’Avella, Christopher , Dowlati, Afshin , Downey, Robert J. , Florsheim, Charles, Grecula, J.C., Hann, Christine L. , Iams, Wade T. , Iyengar, Puneeth , Khalil, Maya, Koczywas, Marianna , Merritt, Robert E. , Mohindra, Nisha , Molina, Julian R. , Moran, César A. , Qin, Angel , Rusthoven, Chad G. , Santana-Dávila, Rafael , Shafique, Michael , Gregory, Kristina M., Hughes, Miranda, Molina, Julian, Ganti, Apar K , Loo, Billy W. , Edelman, Martin J. , Gold, Kathryn Ann , Goldman, Jonathan W. , Kelly, Karen , Pokharel, Saraswati , Puri, Sonam , Sands, Jacob , Waqar, Saiama N

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 13, 2021 | Volume: 19 | Issue: 12 | Pages: 1441-1464

10.6004/jnccn.2021.0058 | PMID 34902832 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management for patients with SCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. This selection for the journal focuses on metastatic (known as extensive-stage) SCLC, which is more common than limited-stage SCLC. Systemic therapy alone can palliate symptoms and prolong survival in most patients with extensive-stage disease. Smoking cessation counseling and intervention should be strongly promoted in patients with SCLC and other high-grade neuroendocrine carcinomas. The “Summary of the Guidelines Updates” section in the SCLC algorithm outlines the most recent revisions for the 2022 update, which are described in greater detail in this revised Discussion text.
Breast cancer—The catalyst of contemporary trials design
Al‐Hilli, Zahraa , Weiss, Anna , Armani, Ava, Blair, Sarah L. , Blair, Sarah L , Boughey, Judy C.

Mayo Clinic

Journal of Surgical Oncology | December 13, 2021 | Volume: 125 | Issue: 1 | Pages: 7-16

10.1002/jso.26722 | PMID 34897706 Get It

AbstractSurgical trials in breast cancer have catalyzed contemporary trial design for solid organ cancers and are a prime example of surgeons taking the lead in clinical trial design. Surgeons have lead trials that have improved patient outcomes and quality of life without sacrificing oncologic safety. We have evolved from radical mastectomy to breast conservation and sentinel node biopsy. Contemporary trial design in breast cancer now focus on personalizing care based on tumor genomics
Repeat computed tomography in recurrent abdominal pain: An evidence synthesis for guidelines for reasonable and appropriate care in the emergency department
Carpenter, Christopher R. , Griffey, Richard T. , Doering, Michelle , Silva, Lucas Oliveira J. e , Bellolio, Fernanda , Upadhye, Suneel , Broder, Joshua , Oliveira J E Silva, Lucas , Bellolio, M Fernanda , Broder, Joshua S , Carpenter, Christopher R , Griffey, Richard T , Mills, Angela M.

Mayo Clinic

Academic Emergency Medicine | December 13, 2021 | Volume: 29 | Issue: 5 | Pages: 630-648

10.1111/acem.14427 | PMID 34897917 Get It

AbstractObjectiveComputed tomography (CT) imaging is frequently obtained for recurrent abdominal pain after a prior emergency department (ED) evaluation. We evaluate the utility of repeat CT imaging following an indeterminate index CT in low‐risk abdominal pain adult ED patients.MethodsAn electronic search was designed for the patient‐intervention‐control‐outcome‐timing (PICOT) question: (P) adult patients with low‐risk, recurrent, and previously undifferentiated atraumatic abdominal pain presenting to the ED after an index‐negative CT within 12 months; (I) repeat CT versus (C) no repeat CT; for (O) abdominal surgery or other invasive procedure, mortality, identification of potentially life‐threatening diagnosis, and hospital and intensive care unit admission rates; and return ED visit (T), all within 30 days. Four reviewers independently selected evidence for inclusion and then synthesized the results around the most prevalent themes of repeat CT timing, diagnostic yield, ionizing radiation exposure, and predictors of repetitive imaging.ResultsAlthough 637 articles and abstracts were identified, no direct evidence was found. Thirteen documents were synthesized as indirect evidence. None of the indirect evidence defined a low‐risk subset of abdominal pain nor did investigators describe whether reimaging occurred for complaints similar to the initial ED evaluation. Included studies did not describe the index CT findings and some reported explanatory findings noted on the original CT for which repeat CTs might have been indicated. The time frame for a repeat CT ranged from hours to 1 year. The frequency of repeat CTs (2%–47%) varied across studies as did the yield of imaging to alter downstream clinical decision making (range = 5%–67%).ConclusionDue to the absence of direct evidence our scoping review is unable to provide high‐quality evidence‐based recommendations upon which to confidently base an imaging practice guideline. There is no evidence to support or refute performing a CT for low‐risk recurrent abdominal pain.
Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography–Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer
Martin, Ting , Savjani, Ricky R. , Pollom, Erqi L., Karnes, R. Jeffrey , Wong, J.K. , Motterle, Giovanni , Tosoian, Jeffrey J. , Klein, Eric A. , Stish, Bradley J. , Dess, Robert T. , Spratt, Daniel E. , Pilar, Avinash , Levin-Epstein, Rebecca , Wedde, Trude B. , Lilleby, Wolfgang , Fiano, Ryan , Stock, Richard G. , Demanes, D. Jeffrey, Huland, Hartwig , Martin, Santiago, Krauss, Daniel , Abu‐Isa, Eyad, Schwen, Zeyad , Pisansky, Thomas M. , Choo, C. Richard, Greco, Stephen , Deville, Curtiland , McNutt, Todd , DeWeese, Theodore L. , Ross, Ashley E. , Ciezki, Jay P. , Nickols, Nicholas G. , Bhat, Prashant , Shabsovich, David , Juarez, Jesus E. , Chong, Natalie, Kupelian, Patrick A. , Reiter, Robert E. , Steinberg, Michael L. , Elashoff, David , Horwitz, Eric M. , Tendulkar, Rahul D. , Czernin, Johannes, Gafita, Andrei , Romero, Tahmineh , Calais, Jérémie , Kishan, Amar U. , Davis, Brian J. , Deville, Curtiland , Spratt, Daniel E , Dess, Robert T , Klein, Eric A , Ma, Ting Martin , Calais, Jeremie , Xiang, Michael H. , Grogan, Tristan , Trock, Bruce J , Reddy, Chandana A. , Merrick, Gregory Stephen , Moran, Brian Joseph , Tran, Phuoc T , Martínez‐Monge, Rafael , Alam, Ridwan , Song, Daniel Y. , Boutros, Paul C. , Rettig, Matthew B. , Zaorsky, Nicholas G. , Berlin, Alejandro , Tward, Jonathan D. , Tilki, Derya

Mayo Clinic

JAMA Network Open | December 13, 2021 | Volume: 4 | Issue: 12 | Pages: e2138550

10.1001/jamanetworkopen.2021.38550 | PMID 34902034 Get It

Why We Need Specialised Centres for Women’s Hearts: Changing the Face of Cardiovascular Care for Women
Gulati, Martha , Hendry, Cara, Parapid, Biljana , Mulvagh, Sharon L.

Mayo Clinic

European Cardiology Review | December 13, 2021 | Volume: 16 | Issue: No issue available | Pages: No page available

10.15420/ecr.2021.49 | PMID 35024054 Get It

Although cardiovascular disease (CVD) is the leading cause of mortality in women globally, cardiovascular care for women remains suboptimal, with poorer outcomes than for men. During the past two decades, there has been an incremental increase in research and publications on CVD in women, addressing sex-specific risk factors, symptoms, pathophysiology, treatment, prevention and identification of inequities in care. Nonetheless, once women have manifested CVD, they continue to have increasingly worse outcomes than men. An approach to addressing these global disparities has been the worldwide establishment of specialised centres providing cardiovascular care for women. These women’s heart centres (WHCs) allow a comprehensive approach to the cardiovascular care of women across the lifespan. The purpose of this article is to define the need for and role of these specialised centres by outlining sex-specific gaps in CVD care, and to provide guidance on components within WHCs that may be considered when establishing such programmes.
Robotic-Assisted vs Nonrobotic-Assisted Minimally Invasive Transforaminal Lumbar Interbody Fusion: A Cost-Utility Analysis
Moniz‐Garcia, Diogo , Akinduro, Oluwaseun O., Biase, Gaetano De, Sousa-Pinto, Bernardo, Jerreld, Daniel J., Dholakia, Ruchita, Borah, Bijan, Nottmeier, Eric, Deen, H. Gordon, Fox, W. Christopher, Bydon, Mohamad, Chen, Selby, Quinones-Hinojosa, Alfredo, Abode-Iyamah, Kingsley, Biase, Gaetano De , Sousa‐Pinto, Bernardo , De Biase, Gaetano , Garcia, Diogo Moniz , Akinduro, Oluwaseun O., Jerreld, Daniel J., Dholakia, Ruchita, Borah, Bijan, Nottmeier, Eric, Deen, H. Gordon, Fox, W. Christopher, Bydon, Mohamad, Chen, Selby, Quinones-Hinojosa, Alfredo, Abode-Iyamah, Kingsley

Mayo Clinic

Neurosurgery | December 13, 2021 | Volume: 90 | Issue: 2 | Pages: 192-198

10.1227/neu.0000000000001779 | PMID 35023874 Get It

BACKGROUND: Management of degenerative disease of the spine has evolved to favor minimally invasive techniques, including nonrobotic-assisted and robotic-assisted minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF). Value-based spending is being increasingly implemented to control rising costs in the US healthcare system. With an aging population, it is fundamental to understand which procedure(s) may be most cost-effective. OBJECTIVE: To compare robotic and nonrobotic MIS-TLIF through a cost-utility analysis. METHODS: We considered direct medical costs related to surgical intervention and to the hospital stay, as well as 1-yr utilities. We estimated costs by assessing all cases involving adults undergoing robotic surgery at a single institution and an equal number of patients undergoing nonrobotic surgery, matched by demographic and clinical characteristics. We adopted a willingness to pay of $50 000/quality-adjusted life year (QALY). Uncertainty was addressed by deterministic and probabilistic sensitivity analyses. RESULTS: Costs were estimated based on a total of 76 patients, including 38 undergoing robot-assisted and 38 matched patients undergoing nonrobot MIS-TLIF. Using point estimates, robotic surgery was projected to cost $21 546.80 and to be associated with 0.68 QALY, and nonrobotic surgery was projected to cost $22 398.98 and to be associated with 0.67 QALY. Robotic surgery was found to be more cost-effective strategy, with cost-effectiveness being sensitive operating room/materials and room costs. Probabilistic sensitivity analysis identified robotic surgery as cost-effective in 63% of simulations. CONCLUSION: Our results suggest that at a willingness to pay of $50 000/QALY, robotic-assisted MIS-TLIF was cost-effective in 63% of simulations. Cost-effectiveness depends on operating room and room (admission) costs, with potentially different results under distinct neurosurgical practices.
COVID-19 Vaccine Hesitancy Among Deployed Personnel in a Joint Environment
Higginson, Jason, Tumin, Dmitry , Kuehhas, Timothy C, DeLozier-Hooks, Susan E, Powell, Carl A, Ramirez, Dale D, Dabelić, Anja, Basso, Michael R.

Mayo Clinic

Military Medicine | December 13, 2021 | Volume: 188 | Issue: 1-2 | Pages: e32-e36

10.1093/milmed/usab518 | PMID 34897473 Get It

ABSTRACT Introduction In the United States, vaccine hesitancy has been identified as a major barrier to vaccination against COVID-19, but attitudes toward COVID-19 vaccination among military personnel are not well understood. We evaluated the prevalence and correlates of COVID-19 vaccine consent or refusal among deployed personnel in a joint environment. Materials and Methods Deidentified data were retrospectively extracted from the electronic medical record of the Military Health System in May 2021. All personnel currently assigned to the deployment area of operations were included in the analysis if their choice to receive the vaccine was known. Personnel characteristics were compared by vaccine acceptance status using chi-square tests, Fisher’s exact tests, or correlation coefficients. This analysis was exempted from Institutional Review Board review. Results The sample included 1,809 individuals, primarily members of the Army (72%) and members of Reserve (53%) or National Guard (27%) units. In the overall sample, 61% accepted the vaccine, with vaccine acceptance rates being lowest among Black or African American personnel (54%; P = .03 for comparison across racial groups) and members of Reserve or National Guard units (59%; P < .001 for comparison by component). No differences in vaccine acceptance were found according to sex or health status (including prior COVID-19 infection). Conclusions Overall vaccine acceptance was greater among deployed military personnel than that reported in the U.S. population as a whole. However, lower vaccine acceptance among personnel from marginalized populations suggests a need to ensure that all service members have sufficient opportunities to have a frank and ongoing discussion with health care providers to address concerns related to vaccination. Additionally, lower vaccine acceptance among Reserve and National Guard personnel indicates a need for innovative educational approaches to counter vaccine hesitancy in the premobilization phase of deployment.